You are here: Industry Insights > Santhera Pharmaceuticals

News List

Santhera, Rutgers Sign Gene Therapy Research Agreements americanpharmaceuticalreview
May 08, 2020
Santhera Pharmaceuticals announces the signing of two agreements with Rutgers, The State University of New Jersey as part of its program to advance gene therapy research for the treatment of LAMA2-deficient congenital muscular dystrophy.
Santhera, Cold Spring Harbor Lab to Investigate Lonodelestat in COVID-19-related ARDS americanpharmaceuticalreview
April 30, 2020
Santhera Pharmaceuticals has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE).
Santhera explores lonodelestat to treat ARDS in Covid-19 patients pharmaceutical-technology
April 30, 2020
Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.
Santhera submits MAA to EMA for Puldysa pharmatimes
May 28, 2019
Santhera Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Puldysa (idebenone) in duchenne muscular dystrophy.
Santhera Pharmaceuticals Opens U.S. Office in Burlington, MA americanpharmaceuticalreview
February 27, 2017
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announced that it will be establishing U.S. operations in Burlington, Mass.